公开(公告)号：WO2015033279A1

公开(公告)日：2015-03-12

申请号：PCT/IB2014/064228

申请日：2014-09-03

Applicant: KANDULA, Mahesh

Inventor： KANDULA, Mahesh

IPC: A61K31/205 ,  A61K31/202 ,  A61P43/00

CPC classification number: A61K31/557 ,  C07C229/12 ,  C07D213/66

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of homocystinuria may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cystathionine beta synthase deficiency or cbs deficiency, is an inherited disorder of the metabolism of the amino acid methionine, often involving cystathionine beta synthase.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物的药物组合物和用于治疗高胱氨酰尿症的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这些组合物可用于治疗胱硫醚β合酶缺乏症或cbs缺乏症，是氨基酸甲硫氨酸的代谢遗传性疾病，常涉及胱硫醚β合酶。

公开(公告)号：WO2015028928A2

公开(公告)日：2015-03-05

申请号：PCT/IB2014064035

申请日：2014-08-23

Applicant: KANDULA MAHESH

Inventor： KANDULA MAHESH

CPC classification number: C07D215/46

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of inflammation and arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis and Sjögren's Syndrome, porphyria cutanea tarda, inflammatory conditions, post-Lyme arthritis, Lyme disease.

Abstract translation: 本发明涉及式I化合物或其可药用盐，以及其多晶型物，溶剂化物，对映异构体，立体异构体和水合物。 包含有效量的式I化合物的药物组合物以及用于治疗炎症和关节炎的方法可以配制用于口服，口腔，直肠，局部，透皮，透粘膜，静脉内，肠胃外施用，糖浆或注射。 此类组合物可用于治疗系统性红斑狼疮，风湿性疾病如类风湿性关节炎和舍格伦氏综合征，迟发性皮肤卟啉症，炎症性疾病，莱姆后关节炎，莱姆病。

公开(公告)号：WO2015022613A1

公开(公告)日：2015-02-19

申请号：PCT/IB2014/063820

申请日：2014-08-09

Applicant: KANDULA, Mahesh

Inventor： KANDULA, Mahesh

IPC: A61K31/00

CPC classification number: A61K31/216 ,  A61K31/155 ,  A61K47/55

Abstract: The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.

Abstract translation: 本发明涉及式I的组合物或其药学上可接受的多晶型物，溶剂合物，对映体，立体异构体和水合物。 药物组合物包含二甲双胍的盐，并且可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射的治疗或预防代谢综合征的方法。 这些组合物可用于治疗糖尿病，肥胖症，脂质疾病，高甘油三酯血症，高血糖症，高胰岛素血症和胰岛素抵抗。

公开(公告)号：WO2014174425A2

公开(公告)日：2014-10-30

申请号：PCT/IB2014060862

申请日：2014-04-20

Applicant: KANDULA MAHESH

Inventor： KANDULA MAHESH

IPC: A61K31/221

CPC classification number: C07C237/20 ,  C07D317/54

Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of orthostasis and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurogenic orthostatic hypotension (NOH), multiple system atrophy (MSA), familial amyloid polyneuropathy (FAP), pure autonomic failure (PAF), Parkinson's disease (PD), Intradialytic hypotension (IDH) or hemodialysis- induced hypotension, Hypotension associated with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS).

Abstract translation: 本发明涉及式I和式II化合物或其药学上可接受的盐，以及多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I或式II化合物的药物组合物，以及用于治疗顽固性和神经系统疾病的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或 注射。 这些组合物可用于治疗神经源性直立性低血压（NOH），多发性系统萎缩（MSA），家族性淀粉样多发性神经病（FAP），纯自主神经衰竭（PAF），帕金森病（PD），室间低血压（IDH）或血液透析 - 引起的低血压，与纤维肌痛综合征（FMS）和慢性疲劳综合征（CFS）相关的低血压。

公开(公告)号：WO2014118649A2

公开(公告)日：2014-08-07

申请号：PCT/IB2014/058090

申请日：2014-01-07

Applicant: KANDULA, Mahesh

Inventor： KANDULA, Mahesh

CPC classification number: C07D211/54

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物的药物组合物，以及用于治疗或预防动脉粥样化血栓形成的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这些组合物可用于治疗或治疗缺血，中风，脑血栓形成，动脉血栓形成，血栓性脑血管，心血管疾病和血块。

公开(公告)号：WO2014091467A3

公开(公告)日：2014-06-19

申请号：PCT/IB2013/060949

申请日：2013-12-14

Applicant: KANDULA, Mahesh

Inventor： KANDULA, Mahesh

IPC: A61K31/56 ,  C07J5/00 ,  C07J7/00 ,  A61P37/00 ,  A61P29/00

Abstract: The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV, and methods for the treatment of autoimmune diseases and inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of Crohn's disease, systemic lupus erythematosus, colitis, arthritis, uvetis, chronic active hepatitis, asthma and lung inflammation.

公开(公告)号：WO2014068459A2

公开(公告)日：2014-05-08

申请号：PCT/IB2013/059637

申请日：2013-10-25

Applicant: KANDULA, Mahesh

Inventor： KANDULA, Mahesh

IPC: A61K31/13

CPC classification number: C07C237/22 ,  A61K47/54 ,  A61K47/542 ,  A61K47/546 ,  A61K47/55 ,  C07D213/75

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of pain and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of partial-onset seizures, diabetic neuropathic pain, back pain and other orthopaedic uses, migraines, oncology, postoperative care, gynaecology, Creutzfeld- Jakob disease, multiple sclerosis, Batten disease, fibromyalgia, Alzheimer's disease, and multiple sclerosis.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物和用于治疗疼痛和神经疾病的方法的药物组合物可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这种组合物可用于治疗部分发作性发作，糖尿病性神经性疼痛，背部疼痛和其他矫形用途，偏头痛，肿瘤学，术后护理，妇科，克雅氏病，多发性硬化症，巴特氏病，纤维肌痛，阿尔茨海默病和 多发性硬化。

公开(公告)号：WO2014041445A3

公开(公告)日：2014-05-08

申请号：PCT/IB2013056709

申请日：2013-08-18

Applicant: KANDULA MAHESH

Inventor： KANDULA MAHESH

IPC: C07D235/18 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61P3/10 ,  A61P9/12 ,  A61P13/12 ,  C07D257/04 ,  C07D403/10 ,  C07D409/06

CPC classification number: C07D257/04 ,  A61K47/542 ,  C07D403/04 ,  C07D403/10 ,  C07D409/06

Abstract: Disclosed are compounds of formula (I) or formula (II), their pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II) are also disclosed. Such compositions may be used for treating diabetes related renal complications, hypertension, albuminuria, heart diseases, ESRD, kidney GFR complications, vascular disease, ventricular septal defect, vascular dilation, high blood pressure, congestive heart failure (CHF), post-myocardial infarction (MI).

Abstract translation: 公开了式（I）或式（II）的化合物，其药学上可接受的盐，以及多晶型物，溶剂合物，对映体，立体异构体和水合物。 还公开了包含有效量的式（I）或式（II）的化合物的药物组合物。 这些组合物可用于治疗糖尿病相关的肾并发症，高血压，白蛋白尿，心脏病，ESRD，肾GFR并发症，血管疾病，室间隔缺损，血管扩张，高血压，充血性心力衰竭（CHF），心肌梗死后 （MI）。

公开(公告)号：WO2014037832A3

公开(公告)日：2014-05-01

申请号：PCT/IB2013056683

申请日：2013-08-16

Applicant: KANDULA MAHESH

Inventor： KANDULA MAHESH

IPC: C07H9/04 ,  A61K31/70 ,  A61P25/08

CPC classification number: C07D493/14 ,  A61K31/357 ,  A61K47/542 ,  A61K47/545

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enatitiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of epilepsy and neurological diseases may be formulated for oral, buccal, rectal topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of convulsions, Lennox -Gastaut syndrome, migraine, bipolar disorder, post traumatic stress disorder.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，硬脂酸酯，立体异构体和水合物。 包含有效量的式I化合物和用于治疗癫痫和神经疾病的方法的药物组合物可以配制用于口服，口腔，直肠局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 此类组合物可用于治疗惊厥，Lennox-Gastaut综合征，偏头痛，双相情感障碍，创伤后应激障碍。

公开(公告)号：WO2014057407A2

公开(公告)日：2014-04-17

申请号：PCT/IB2013059146

申请日：2013-10-06

Applicant: KANDULA MAHESH

Inventor： KANDULA MAHESH

CPC classification number: C07H15/207

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of metabolic syndrome, insulin resistance, glucose intolerance, hyperinsulinemia, diabetes mellitus, diabetes insipidus, hyperglycemia and diabetic complications.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐，以及其多晶型物，溶剂合物，对映体，立体异构体和水合物。 包含有效量的式I化合物的药物组合物，以及用于治疗或预防糖尿病的方法可以配制用于口服，口腔，直肠，局部，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 此类组合物可用于治疗代谢综合征，胰岛素抵抗，葡萄糖耐受不良，高胰岛素血症，糖尿病，尿崩症，高血糖症和糖尿病并发症。